The trajectory of Sildenafil presents a complex picture for shareholders. While the initial launch generated substantial gains, the lapse of its exclusive rights opened the avenue to generic competitors, dramatically https://bookmarkspedia.com/story7360685/viagra-and-big-pharma-a-risky-opportunity